<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989819</url>
  </required_header>
  <id_info>
    <org_study_id>I10 023</org_study_id>
    <nct_id>NCT01989819</nct_id>
  </id_info>
  <brief_title>Primary Sjögren Syndrome</brief_title>
  <acronym>NeuroSenSS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often
      involving the central and peripheral nervous systems. Fifteen to twenty percent of patients
      with the primary Sjögren's syndrome have neurological complications involving the peripheral
      nervous system. Although some patients have large fiber neuropathy, around forty percent of
      patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic
      studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms,
      some have been shown to have small fiber neuropathy (SFN). A recent study proved that more
      than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.

      The aim of this study will be to investigate the occurrence of small fiber neuropathy in
      patients with pSS and neuropathic pain with normal electromyographic studies and to determine
      the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or
      auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is
      a valuable tool to diagnose small fiber neuropathy and the method has been widely validated.
      A skin biopsy will be performed in patients and control and will allow quantification of
      small fiber density in skin sample along with measurement of sweat gland innervation.
      Moreover, pathophysiological studies will be carried on in order to evaluate the causal
      relationship between cellular and humoral inflammation and small fiberneuropathy.

      Recent studies have pointed out the inconstant efficacy of both corticosteroid and
      immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small
      fiber neuropathy in these patients may help designing new therapeutic strategies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>To evaluate the cutaneous lymphocytic infiltration</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cutaneous infiltration T, B and Th17</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>patients with Sjögren's syndrome</arm_group_label>
    <description>A skin biopsy will be performed in patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>A skin biopsy will be performed in control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non auto-immune small fiber neuropathies</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <arm_group_label>patients with Sjögren's syndrome</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sjögren's syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pSS according to revised European criteria and exhibiting neuropathic
             pain without any electromyographic abnormality will be included (Group I).

          -  Age of entry into the study ≥ 18 yrs (both groups).

          -  Affiliated or profit patient of a social security system (both groups).

          -  Informed consent signed up (both groups).

        Exclusion Criteria:

          -  Chronic alcoholism

          -  Type I or type II diabetes

          -  Peripheral neuropathy unrelated to pSS complications

          -  Coagulation disease

          -  Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil

          -  Porphyria, methemoglobinemia

          -  Patients under measure of maintenance of justice.

          -  Patients unable to understand or to participate to the study.

          -  Child and major patients making the object of a measure of lawful protection.

          -  Patients deprived of freedom.

          -  Pregnant, nursing women.

          -  Participation in biomedical research within one month prior to inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Laure FAUCHAIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Laure FAUCHAIS, MD</last_name>
    <phone>(+33) 5 55 05 65 03</phone>
    <email>anne-laure.fauchais@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH d'Albi</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Madaule, MD</last_name>
      <phone>(+33) 5 63 47 42 86</phone>
      <email>serge.madaule@ch-albi.rss.fr</email>
    </contact>
    <investigator>
      <last_name>Serge Madaule, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Mercié</last_name>
      <phone>(+33) 5 56 79 57 28</phone>
      <email>patrick.mercie@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Mercié, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Brive</name>
      <address>
        <city>Brive la Gaillarde</city>
        <zip>19312</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Abraham, MD</last_name>
      <phone>(+33) 5 55 92 60 40</phone>
      <email>BRUNO.ABRAHAM@ch-brive.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno ABRAHAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Yves Hatron</last_name>
      <phone>(+33) 3 20 44 42 95</phone>
      <email>pyhatron@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Hatron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure FAUCHAIS, MD</last_name>
      <phone>(+33) 5 55 05 86 21</phone>
      <email>anne-laure.fauchais@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Laure FAUCHAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Brevet, MD</last_name>
      <phone>(+33) 5 65 55 22 80</phone>
      <email>f.brevet@ch-rodez.fr</email>
    </contact>
    <investigator>
      <last_name>Françoise BREVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ARLET, MD</last_name>
      <phone>(+33) 5 61 77 95 50</phone>
      <email>arlet.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe ARLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

